Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.

• Status: Terminated
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Safety and efficacy (measured by spirometry) of UK-432,097 administration will be tested in patients with chronic obstructive pulmonary disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Adenosine

Criteria

Inclusion Criteria:

• Patients with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD) and who meet the criteria for Stage II-III disease

• Patients must have a smoking history of at least 10 pack-years

• Patients must have stable disease for at least 1 month prior to screening.

Exclusion Criteria:

• More than 2 exacerbations of COPD in the preceding year

• History of a lower respiratory tract infection or significant disease instability during the month proceding screening or during the time between screen and randomization.

• History or presence of respiratory failure, cor pulmonale or right ventricular failure